CD151抗体;CD151 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using CD151 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using CD151 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues using CD151 mouse mAb with DAB staining.    

  
  

CD151. a member of the tetraspanin transmembrane protein family, plays a critical role in regulating cellular adhesion, migration, and signaling by organizing membrane protein complexes. It interacts with integrins (e.g., α3β1. α6β4) and other tetraspanins to modulate cell-matrix interactions, influencing processes like angiogenesis, wound healing, and immune responses. Dysregulation of CD151 is linked to cancer progression, metastasis, and poor prognosis, as it enhances tumor cell invasiveness and supports vascularization.

CD151 antibodies are tools developed to study its biological functions or target it therapeutically. Monoclonal antibodies against CD151 have been used to block its interactions with partner proteins, disrupt signaling pathways, or inhibit tumor growth in preclinical models. Some antibodies also serve as diagnostic markers for diseases associated with CD151 overexpression, such as certain carcinomas. Research has explored their potential in immunotherapy, though challenges like specificity and off-target effects remain.

Recent studies focus on engineering CD151 antibodies for improved affinity and minimal immunogenicity, with some advancing into early-phase clinical trials. These antibodies hold promise for precision oncology but require further validation to ensure efficacy and safety in human applications.